Harbor Capital Advisors Inc. Buys 3,804 Shares of Castle Biosciences, Inc. $CSTL

Harbor Capital Advisors Inc. boosted its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 22.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,399 shares of the company’s stock after purchasing an additional 3,804 shares during the period. Harbor Capital Advisors Inc. owned about 0.07% of Castle Biosciences worth $417,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in CSTL. Vanguard Group Inc. grew its position in Castle Biosciences by 11.7% during the 1st quarter. Vanguard Group Inc. now owns 2,047,565 shares of the company’s stock worth $40,992,000 after acquiring an additional 215,030 shares during the last quarter. Principal Financial Group Inc. grew its position in Castle Biosciences by 2.2% during the 1st quarter. Principal Financial Group Inc. now owns 1,467,873 shares of the company’s stock worth $29,387,000 after acquiring an additional 32,208 shares during the last quarter. Wellington Management Group LLP grew its position in Castle Biosciences by 14.7% during the 1st quarter. Wellington Management Group LLP now owns 828,528 shares of the company’s stock worth $16,587,000 after acquiring an additional 106,408 shares during the last quarter. Acadian Asset Management LLC grew its position in Castle Biosciences by 65.4% during the 1st quarter. Acadian Asset Management LLC now owns 676,066 shares of the company’s stock worth $13,527,000 after acquiring an additional 267,416 shares during the last quarter. Finally, Nuveen LLC bought a new stake in Castle Biosciences during the 1st quarter worth $13,450,000. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Stock Up 4.0%

Shares of NASDAQ CSTL opened at $24.41 on Friday. The stock has a market capitalization of $708.13 million, a P/E ratio of -69.74 and a beta of 1.07. The company has a 50-day moving average price of $20.07 and a 200-day moving average price of $19.37. Castle Biosciences, Inc. has a 1 year low of $14.59 and a 1 year high of $35.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.85 and a quick ratio of 6.69.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.66. The firm had revenue of $86.18 million during the quarter, compared to analysts’ expectations of $71.53 million. Castle Biosciences had a negative net margin of 2.73% and a positive return on equity of 2.37%. Castle Biosciences has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Insider Buying and Selling at Castle Biosciences

In related news, insider Derek J. Maetzold sold 1,339 shares of the firm’s stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $21.97, for a total transaction of $29,417.83. Following the transaction, the insider directly owned 65,666 shares of the company’s stock, valued at $1,442,682.02. This trade represents a 2.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

CSTL has been the topic of a number of research reports. Zacks Research upgraded Castle Biosciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Wall Street Zen upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 10th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $37.00 price target on shares of Castle Biosciences in a research report on Tuesday, September 9th. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Castle Biosciences currently has an average rating of “Moderate Buy” and an average target price of $37.00.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.